A pioneering biotechnology start-up which specializes in developing a non-invasive liquid test to detect early stages of cancer recurrence. The main vision is to save as many lives as possible by discovering the recurrence of cancer at a time when it can still be treated.
Our scientific team has in-depth expertise in molecular biology and is dedicated to maximize LIBI-Diagnostics achievements.
Our scientific team has in-depth expertise in molecular biology and is dedicated to maximize LIBI-Diagnostics achievements.
CHANGING THE FUTURE
OF CANCER TREATMENT
OF CANCER TREATMENT
FUTURE
LIBI Diagnostics is a gene-biomarker start-up for the early detection of cancer, powered by next-generation bio-liquid tests.
Using state-of-the-art Next-Generation Sequencing (NGS) technology, LIBI-Diagnostics customising tests for each patient by detecting alterations of Aurora Kinase A in blood and/or voided urine samples compared to the genomic expression data in the primary tumor
Currently oncology patients are notified that the cancer is in complete remission or that there is a complete response to treatment, when tumors / metastases are no longer detected on imaging devices.
However, the non-identification in itself does not prove that the patient condition is cancer-free, since the high death rates due to recurrence of cancer indicate that not all tumors / metastases have been destroyed.
Periodic imaging tests, while performed to detect recurrence, give a binary result, so that when recurrence is detected, the patient is already in the danger zone and his chances of survival decrease dramatically.
However, the non-identification in itself does not prove that the patient condition is cancer-free, since the high death rates due to recurrence of cancer indicate that not all tumors / metastases have been destroyed.
Periodic imaging tests, while performed to detect recurrence, give a binary result, so that when recurrence is detected, the patient is already in the danger zone and his chances of survival decrease dramatically.
Early Diagnosis Can Prevent
Why early detection is important?
Aggressive & Invasive Treatments
Mortality
Unnecessary High Medical Expenses
cancer deaths worldwide
10 M
lung cancer cases
2.21 M
cancer cases worldwide
19.3 M
breast cancer cases
2.26 M
Libi-Diagnostics provides a practical and effective answer to the the inefficiency of periodic imaging tests. LIBI diagnoses recurrent cancerous development in an early stage with only few cells and provides sufficient information to neutralize that early development. In this way, it is possible to spare the patient aggressive treatments, unnecessary suffering and maintain his good chances of survival.
Early diagnosis of cancer is crucial in most types of cancers.
Learn More
LIBI Diagnostics Leadership
Galit Lisaey
Established Gal.IT Data Integrity Consulting which
implements Data Integrity processes, including risk-based computer system validation management. She was the IT Team leader for the Information Technology group for Teva pharmaceutical labs. Recieved an MSc degree in Animal Studies from the Hebrew University of Jerusalem.
implements Data Integrity processes, including risk-based computer system validation management. She was the IT Team leader for the Information Technology group for Teva pharmaceutical labs. Recieved an MSc degree in Animal Studies from the Hebrew University of Jerusalem.
David Risin, CEO
Served 15years as Combat Captain under the Ministry of
Homeland Security. Holds a law degree and Master’s in real estate. In collaboration with the medical experts at Rambam Hospital, he led the innovative and unique treatment of his daughter Libby and saved her from certain death.
Homeland Security. Holds a law degree and Master’s in real estate. In collaboration with the medical experts at Rambam Hospital, he led the innovative and unique treatment of his daughter Libby and saved her from certain death.
Ph.D. in molecular biology of type 2 diabetes, Technion-
Israel Institute of Technology, 2010. She has established
several labs at the Technion medicine faculty and served as lab and project manager in varied cancer fields, targeting for early diagnosis and better treatments.
Israel Institute of Technology, 2010. She has established
several labs at the Technion medicine faculty and served as lab and project manager in varied cancer fields, targeting for early diagnosis and better treatments.
Dr Shiri Karni - Ashkenazi, PhD CTO
Mark Trauner Faculty Scholar in Neuro-Oncology. Professor
in Department of Genetics and Department of Microbiology and Immunology, Albert Einstein College of Medicine.
in Department of Genetics and Department of Microbiology and Immunology, Albert Einstein College of Medicine.
Ganjam V. Kalpana, Ph.D.
Contact Us
STAY UPDATED
Change the world with your support.
A huge step for LIBI-Diagnostics in saving the lives of cancer patients
A huge step for LIBI-Diagnostics in saving the lives of cancer patients
SUBSCRIBE
Follow us on social media
© 2021 LIBI Diagnostics Ltd. All rights reserved
